Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review. (January 2021)

• Record Type: Journal Article
• Authors: Kim, Christine; Han, Joseph; Wu, Tara; Bachert, Claus; Fokkens, Wytske; Hellings, Peter; Hopkins, Claire; Lee, Stella; Mullol, Joaquim; Lee, Jivianne T.
• Is Part Of: Otolaryngology--head and neck surgery. Volume 164:Number 1(2021)
• Page Start: 57
• Page End: 66
• Publication Date: 2021-01
• Subjects: chronic rhinosinusitis -- nasal polyposis -- biologics; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0194599820939964
• Languages: English
• ISSNs: 0194-5998

Abstract

Objective: To review the current literature regarding the role of biologics in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). Data Sources: PubMed/MEDLINE, EMBASE, Cochrane Review, ClinicalTrials.gov Review Methods: We conducted a comprehensive review of the literature on clinical studies investigating the efficacy of emerging biologics in CRSwNP, with a focus on randomized controlled trials. Conclusions: There appears to be promising evidence to support the safety and efficacy of biologics in CRSwNP with and without asthma for select patients. However, additional large-scale randomized studies with longer follow-up are necessary to determine which patients would benefit the most from these novel systemic treatments. Implications for Practice: Chronic rhinosinusitis with nasal polyposis refractory to medical and surgical therapy remains a challenging clinical problem for otolaryngologists. However, emerging biologic therapies may offer a new therapeutic option for such patients with recalcitrant disease.